Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas

AIM: The Phase Ib GERSHWIN study (NCT01680991) assessed the pharmacokinetic (PK) profile of obinutuzumab following multiple intravenous (i.v.) doses to Chinese patients with B‐cell lymphomas, and compared findings with previous obinutuzumab PK studies in mainly Caucasian (non‐Chinese) patients. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, John, Qin, Yan, Zhu, Jun, Song, Yuqin, Shen, Zhixiang, Du, Xin, Jamois, Candice, Brewster, Michael, Shi, Yuankai, Shi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465338/
https://www.ncbi.nlm.nih.gov/pubmed/28072473
http://dx.doi.org/10.1111/bcp.13232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465338/
https://www.ncbi.nlm.nih.gov/pubmed/28072473
http://dx.doi.org/10.1111/bcp.13232

Ejemplares similares